Infarmed withdraws a batch of Salofalk medicine for intestinal inflammation from the market

▤ Summary

Infarmed ordered the immediate withdrawal of one batch of Salofalk used for intestinal inflammation after detecting a serialization deviation. Dr. Falk Pharma Portugal will collect the affected batch from the market. The regulator told stockholders not to sell, dispense, or administer the batch and to return it. Patients currently using the medicine should not stop treatment without medical advice and should contact their doctor about a possible alternative.

▦ Linked Companies